Privacy, Disclaimer & General Conditions

News Galapagos, advised by Argo, raises EUR 363.9 million gross proceeds in a U.S. public Offering
21 April 2017

Argo advised Galapagos, a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, on its underwritten public offering of 4,312,500 American Depositary Shares (“ADSs”), for gross proceeds of €363.9 million.

Back to news
Stay in the loop.